LipoScience to Discuss 2014 Guidance on Fourth Quarter 2013 Financial Results Conference Call

LipoScience logo

RALEIGH, N.C., Nov. 21, 2013 (GLOBE NEWSWIRE) -- LipoScience, Inc. (Nasdaq:LPDX) today announced that it will discuss revenue guidance for 2014 on the Company's Fourth Quarter 2013 conference call rather than on December 3, 2013 as previously announced. Management believes this timing will allow for greater visibility into factors that may influence 2014 revenue, including implementation of the Affordable Care Act (ACA) and publication of the latest laboratory fee schedule by the Centers of Medicare and Medicaid Services (CMS).

In addition, new practice guidelines from the American College of Cardiology (ACC)/American Heart Association (AHA) Task Force were released online on November 12, 2013, subsequent to the Company's announcement of the timing of 2014 guidance. Although on balance these guidelines are not negative for the Company, the issuance of the new practice guidelines represents a substantial change from prior ACC/AHA guidelines. It will take time to assess and respond to any potential confusion in the marketplace that may result from the ongoing dialogue surrounding implementation of the new guidelines.

About LipoScience, Inc.

LipoScience, Inc. is pioneering a new field of personalized diagnostics based on nuclear magnetic resonance (NMR) technology. The company's first proprietary diagnostic test, the NMR LipoProfile® test, measures the number of low-density lipoprotein particles (LDL-P) in a blood sample and provides physicians and their patients with actionable information to personalize management of risk for heart disease. To date, over 10 million NMR LipoProfile tests have been ordered. LipoScience's automated clinical analyzer, Vantera®, has been cleared by the U.S. Food and Drug Administration (FDA). It requires no previous knowledge of NMR technology to operate and has been designed to dramatically simplify complex technology through ease of use and walk-away automation. The Vantera Clinical Analyzer will be placed with national and regional clinical laboratories.

LipoScience is striving toward the NMR LipoProfile test becoming the preferred choice by physicians for management of cardiovascular disease. For further information on LipoScience, please visit www.liposcience.com and www.theparticletest.com.

CONTACT: Investor Relations ICR, Inc. Bob Yedid Senior Vice President 646-277-1250 bob.yedid@icrinc.com LipoScience, Inc. Tori Hall tori.hall@liposcience.com (919) 256-1046

Source:LipoScience, Inc.